Dr. Kishtagari's area of specialization is in the treatment of myeloid malignancies. He is also focused on clonal hematopoiesis, a risk factor for leukemia, cardiovascular disease, and all-cause mortality. During his fellowship training, Dr. Kishtagari investigated non-cytotoxic epigenetic therapy for acute myeloid leukemia. He is passionate about drug development in myeloid malignancies, clonal hematopoiesis, and bone marrow failure disorders. Dr. Kishtagari was awarded the American Society of Hematology (ASH) Hematology Opportunities for the Next-Generation of Research Scientists (HONORS) award for his research in hematologic malignancies. He has received numerous awards including the ASH abstract achievement award and Case Comprehensive Cancer Center VeloSano Catalyst award for highly innovative projects.